Actively Recruiting
Study of mRNA Therapy ABO2203 for Adults With Relapsed or Refractory CD19-Positive B-cell Non-Hodgkin Lymphoma
Led by Ruijin Hospital · Updated on 2025-07-18
56
Participants Needed
1
Research Sites
47 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and early effectiveness of a new mRNA treatment called ABO2203 that targets CD19CD3 T cells in adults with relapsed or refractory CD19-positive B-cell Non-Hodgkin Lymphoma B-NHL. This study includes both a dose escalation phase and a dose expansion phase to explore the treatments potential and appropriate dosing. Participants will receive ABO2203 either by subcutaneous injection or intravenous infusion. The study is interventional with a single experimental arm where patients are treated with ABO2203. The trial spans from the initial dose through 30 days after the last dose, focusing on evaluating the treatments effects and behavior in the body. During the study, participants will be closely monitored for safety and response. Researchers will assess the treatments impact on measurable lymphoma lesions and collect data on how the drug is processed and affects the body. The study requires regular evaluations including physical exams and laboratory tests to ensure participant safety and to measure outcomes. The total age range for participants is 18 to 75 years.
CONDITIONS
Brief Title
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Research Team
P
Pei miao Zhang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
